|
|||||
|
|
Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer |
|
| Authors: | S. Gundersen S. Kvinnsland S. Lundgren O. Klepp E. Lund O. Børmer H. Høst |
| Affiliation: | (1) Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, 0310 Montebello, Oslo 3, Norway;(2) Department of Medical Oncology and Radiotherapy, Regional and University Hospital Trondheim, 7006 Trondheim, Norway;(3) Department of Therapeutic Oncology and Radiophysics, University of Bergen, 5021 Haukeland, Bergen, Norway;(4) Department of Medical Oncology and Radiotherapy, Office for Clinical Investigations, The Norwegian Radium Hospital, 0310 Montebello, Oslo 3, Norway;(5) Central Laboratory, The Norwegian Radium Hospital, 0310 Montebello, Oslo 3, Norway |
| Abstract: | Summary One-hundred and seventy patients with estrogen receptor positive ( 10 pmol/g protein) advanced breast cancer have been treated in a prospective randomized study either with continuous tamoxifen 30 mg × 1 daily (TAM), or with TAM 30 mg × 1 daily for 8 weeks alternating with medroxyprogesterone acetate 500 mg × 2 daily for 8 weeks (TAM/HD-MPA). The response rate was 62% in the group treated with cyclic TAM/HD-MPA versus 41% in the TAM alone group (p = 0.02). There was no significant difference in duration of remissions or survival. |
| Keywords: | advanced breast cancer cyclic treatment endocrine therapy estrogen receptor medroxyprogesterone acetate tamoxifen |
| 本文献已被 SpringerLink 等数据库收录！ | |